Editorial: What have we lost in the wake of the rosiglitazone controversy?
Stuart W
SW
Zarich
Richard W
RW
Nesto
D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004338:Drug Combinations; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000453:epidemiology; D018570:Risk Assessment; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome; D028761:Withholding Treatment / Q000706:statistics & numerical data
D001786:Blood Glucose; D004338:Drug Combinations; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone